Novo Nordisk

For Novo Nordisk, The Lewin Group conducted a study to estimate the national economic costs associated with undiagnosed diabetes mellitus (UDM). This study builds on previous work on the national costs associated with diagnosed diabetes mellitus. Lewin used a Cost of Diabetes Model that combines data from multiple sources to estimate the national prevalence of UDM in 2007; to quantify differences in health care use patterns for a proxy for the population with UDM compared to a population with no history of diabetes; to estimate the proportion of national health care use and expenditures associated with UDM; and to estimate the loss in national productivity.  The study is published in the journal Population Health Management.

"Throughout the engagement, Lewin consultants listened to us and delivered superb analyses and thoughtful guidance–not canned solutions."  NONPROFIT HEALTH SYSTEM